Lomonaco Stephanie L, Kahana Sarit, Blass Michal, Brody Yehuda, Okhrimenko Hana, Xiang Cunli, Finniss Susan, Blumberg Peter M, Lee Hae-Kyung, Brodie Chaya
William and Karen Davidson Laboratory of Cell Signaling and Tumorigenesis, Hermelin Brain Tumor Center, Department of Neurosurgery, Henry Ford Hospital, Detroit, Michigan 48202, USA.
J Biol Chem. 2008 Jun 20;283(25):17731-9. doi: 10.1074/jbc.M801727200. Epub 2008 Apr 23.
The mechanism underlying the important role of protein kinase Cdelta (PKCdelta) in the apoptotic effect of etoposide in glioma cells is incompletely understood. Here, we examined the role of PKCdelta in the activation of Erk1/2 by etoposide. We found that etoposide induced persistent activation of Erk1/2 and nuclear translocation of phospho-Erk1/2. MEK1 inhibitors decreased the apoptotic effect of etoposide, whereas inhibitors of p38 and JNK did not. The activation of Erk1/2 by etoposide was downstream of PKCdelta since the phosphorylation of Erk1/2 was inhibited by a PKCdelta-KD mutant and PKCdelta small interfering RNA. We recently reported that phosphorylation of PKCdelta on tyrosines 64 and 187 was essential for the apoptotic effect of etoposide. Using PKCdeltatyrosine mutants, we found that the phosphorylation of PKCdeltaon these tyrosine residues, but not on tyrosine 155, was also essential for the activation of Erk1/2 by etoposide. In contrast, nuclear translocation of PKCdelta was independent of its tyrosine phosphorylation and not necessary for the phosphorylation of Erk1/2. Etoposide induced down-regulation of kinase phosphatase-1 (MKP-1), which correlated with persistent phosphorylation of Erk1/2 and was dependent on the tyrosine phosphorylation of PKCdelta. Moreover, silencing of MKP-1 increased the phosphorylation of Erk1/2 and the apoptotic effect of etoposide. Etoposide induced polyubiquitylation and degradation of MKP-1 that was dependent on PKCdelta and on its tyrosine phosphorylation. These results indicate that distinct phosphorylation of PKCdeltaon tyrosines 64 and 187 specifically activates the Erk1/2 pathway by the down-regulation of MKP-1, resulting in the persistent phosphorylation of Erk1/2 and cell apoptosis.
蛋白激酶Cδ(PKCδ)在拓扑替康对胶质瘤细胞的凋亡作用中发挥重要作用的潜在机制尚未完全明确。在此,我们研究了PKCδ在拓扑替康激活细胞外信号调节激酶1/2(Erk1/2)中的作用。我们发现拓扑替康可诱导Erk1/2的持续激活以及磷酸化Erk1/2的核转位。MEK1抑制剂可降低拓扑替康的凋亡作用,而p38和JNK抑制剂则无此作用。拓扑替康对Erk1/2的激活作用位于PKCδ下游,因为Erk1/2的磷酸化被PKCδ-KD突变体和PKCδ小干扰RNA所抑制。我们最近报道,PKCδ的酪氨酸64和187位点的磷酸化对于拓扑替康的凋亡作用至关重要。使用PKCδ酪氨酸突变体,我们发现这些酪氨酸残基而非酪氨酸155位点的PKCδ磷酸化对于拓扑替康激活Erk1/2也至关重要。相反,PKCδ的核转位与其酪氨酸磷酸化无关,且对于Erk1/2的磷酸化并非必需。拓扑替康可诱导激酶磷酸酶-1(MKP-1)的下调,这与Erk1/2的持续磷酸化相关,且依赖于PKCδ的酪氨酸磷酸化。此外,沉默MKP-1可增加Erk1/2的磷酸化以及拓扑替康的凋亡作用。拓扑替康可诱导MKP-1的多聚泛素化和降解,这依赖于PKCδ及其酪氨酸磷酸化。这些结果表明,PKCδ酪氨酸64和187位点的特异性磷酸化通过下调MKP-1特异性激活Erk1/2通路,导致Erk1/2的持续磷酸化和细胞凋亡。